A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease

被引:167
作者
Ambrosi, Giulia [1 ,2 ]
Cerri, Silvia [1 ]
Blandini, Fabio [1 ]
机构
[1] Natl Neurol Inst C Mondino, Lab Funct Neurochem, Ctr Res Neurodegenerat Dis, I-27100 Pavia, Italy
[2] Univ Pavia, Dept Brain & Behav Sci, I-27100 Pavia, Italy
关键词
Glutamate receptors; Excitotoxicity; Calcium; Metabolic shift; NMDARs and mGluR5 antagonists; METABOTROPIC GLUTAMATE RECEPTORS; LEVODOPA-INDUCED DYSKINESIA; REDUCES NIGROSTRIATAL DEGENERATION; EXCITATORY SYNAPTIC-TRANSMISSION; D-ASPARTATE ANTAGONISTS; ON-OFF PHENOMENA; NMDA RECEPTOR; SUBSTANTIA-NIGRA; RODENT MODEL; NEURODEGENERATIVE DISORDERS;
D O I
10.1007/s00702-013-1149-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Increased levels of extracellular glutamate and hyperactivation of glutamatergic receptors in the basal ganglia trigger a critical cascade of events involving both intracellular pathways and cell-to-cell interactions that affect cell viability and promote neuronal death. The ensemble of these glutamate-triggered events is responsible for excitotoxicity, a phenomenon involved in several pathological conditions affecting the central nervous system, including a neurodegenerative disease such as Parkinson's disease (PD). PD is an age-related disorder caused by the degeneration of dopaminergic neurons within the substantia nigra pars compacta, with a miscellaneous pathogenic background. Glutamate-mediated excitotoxicity may be involved in a lethal vicious cycle, which critically contributes to the exacerbation of nigrostriatal degeneration in PD. Since excitotoxicity is a glutamate-receptor-mediated phenomenon, growing interest and work have been dedicated to the research for modulators of glutamate neurotransmission that might enable new therapeutic interventions to slow down the neurodegenerative process and ameliorate PD motor symptoms.
引用
收藏
页码:849 / 859
页数:11
相关论文
共 102 条
[11]
Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice [J].
Battaglia, G ;
Busceti, CL ;
Molinaro, G ;
Biagioni, F ;
Storto, M ;
Fornai, F ;
Nicoletti, F ;
Bruno, V .
JOURNAL OF NEUROSCIENCE, 2004, 24 (04) :828-835
[12]
Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [J].
Battaglia, Giuseppe ;
Busceti, Carla L. ;
Molinaro, Gemma ;
Biagioni, Francesca ;
Traficante, Anna ;
Nicoletti, Ferdinando ;
Bruno, Valeria .
JOURNAL OF NEUROSCIENCE, 2006, 26 (27) :7222-7229
[13]
AFQ056 Treatment of Levodopa-Induced Dyskinesias: Results of 2 Randomized Controlled Trials [J].
Berg, Daniela ;
Godau, Jana ;
Trenkwalder, Claudia ;
Eggert, Karla ;
Csoti, Iiona ;
Storch, Alexander ;
Huber, Heiko ;
Morelli-Canelo, Monica ;
Stamelou, Maria ;
Ries, Vincent ;
Wolz, Martin ;
Schneider, Christine ;
Di Paolo, Therese ;
Gasparini, Fabrizio ;
Hariry, Sam ;
Vandemeulebroecke, Marc ;
Abi-Saab, Walid ;
Cooke, Katy ;
Johns, Donald ;
Gomez-Mancilla, Baltazar .
MOVEMENT DISORDERS, 2011, 26 (07) :1243-1250
[14]
Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease [J].
Blandini, F ;
Nappi, G ;
Greenamyre, JT .
ANNALS OF NEUROLOGY, 2001, 49 (04) :525-529
[15]
Breysse N, 2002, J NEUROSCI, V22, P5669
[16]
Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs [J].
Bruno, V ;
Battaglia, G ;
Copani, A ;
D'Onofrio, M ;
Di Iorio, P ;
De Blasi, A ;
Melchiorri, D ;
Flor, PJ ;
Nicoletti, F .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2001, 21 (09) :1013-1033
[17]
Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease [J].
Chan, Hugh ;
Paur, Helen ;
Vernon, Anthony C. ;
Zabarsky, Virginia ;
Datla, Krishna P. ;
Croucher, Martin J. ;
Dexter, David T. .
PARKINSONS DISEASE, 2010, 2010
[18]
AMPA receptors as drug targets in neurological disease - advantages, caveats, and future outlook [J].
Chang, Philip K. -Y. ;
Verbich, David ;
McKinney, R. Anne .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2012, 35 (12) :1908-1916
[19]
A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations [J].
Clarke, CE ;
Cooper, JA ;
Holdich, TAH .
CLINICAL NEUROPHARMACOLOGY, 2001, 24 (03) :133-138
[20]
Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing parkinsonian deficits in rats [J].
Coccurello, R ;
Breysse, N ;
Amalric, M .
NEUROPSYCHOPHARMACOLOGY, 2004, 29 (08) :1451-1461